Raynara Pereira Camargo

Raynara Pereira Camargo

Auto-generated profile, based on publicly available information

Raynara Pereira Camargo

Pontifical Catholic University of Sao Paulo

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2026 in European Journal of Ophthalmology
Verified
Journal Article
Closed access
LCLidia Cheidde
Lidia Cheidde
Dillan Cunha AmaralDillan Cunha Amaral
Dillan Cunha Amaral
YAYuri Aleksander-Ivanov
Yuri Aleksander-Ivanov
RCRaynara Pereira Camargo
Raynara Pereira Camargo
APArthur Tiemann Paião
Arthur Tiemann Paião
MMMário Luiz Ribeiro Monteiro
Mário Luiz Ribeiro Monteiro
Introduction: Understanding the modifiable risk factors for Graves’ orbitopathy (GO) is crucial for its prevention. Methods: We searched PubMed, Embase, and Web of Science databases following PRISMA guidelines. Studies reporting the presence of GO compared to patients with Graves’ disease (GD) without orbitopathy or healthy controls were included. Statistical analysis was performed using Review Manager 5.4.1. Results: Twenty-two studies met the inclusion criteria. Smoking increased the risk of GO, with odds ratios (ORs) of 2.00 (95% CI [1.47, 2.72]; p < 0.0001) for current smokers and 1.77 (95% CI [1.33, 2.37]; p = 0.0001) for former smokers, compared with GD patients without orbitopathy. Thyroidectomy was associated with a higher OR of Graves’ disease without orbitopathy, supporting a protective effect against orbitopathy (OR 2.53; 95% CI [1.03, 6.22]; p = 0.04). However, radioiodine therapy did not show a significant association (OR 0.89; 95% CI [0.42, 1.91]; p = 0.77). Biomarkers, including vitamin D ( p = 0.63), FT3 ( p = 0.89), FT4 ( p = 0.59), and TSH ( p = 0.40), showed no significant differences. In comparison to healthy controls, smoking remained a major risk factor for GO (OR 4.81; 95% CI [1.39, 16.70]; p = 0.01), while elevated FT4 (MD 8.87; 95% CI [1.64, 16.10]; p = 0.02) and decreased TSH (MD −1.23; 95% CI [-2.25, −0.20]; p = 0.02) levels were found in the GO groups. Conclusion: Our analysis provides a comprehensive understanding of clinical and biomarker-based risk factors to guide targeted prevention strategies.